Discovery of Thieno[3,2-]pyridine-5-carboxamide and 2,3-Difluorobenzamide Negative Allosteric Modulators of Metabotropic Glutamate Receptor Subtype 5
Authors
Crocker
KE
Katherine E
,
Henderson
SH
Scott H
,
Capstick
RA
Rory A
,
Whomble
DL
David L
,
Bender
AM
Aaron M
,
Felts
AS
Andrew S
,
Han
C
Changho
,
Engers
JL
Julie L
,
Billard
NB
Natasha B
,
Maurer
MA
Mallory A
,
Cho
HP
Hyekyung P
,
Rodriguez
AL
Alice L
,
Niswender
CM
Colleen M
,
O'Neill
J
Jordan
,
Watson
KJ
Katherine J
,
Chang
S
Sichen
,
Blobaum
AL
Anna L
,
Boutaud
O
Olivier
,
Peng
W
Weimin
,
Rook
JM
Jerri M
,
Conn
PJ
P Jeffrey
,
Lindsley
CW
Craig W
,
Temple
KJ
Kayla J
.
ACS medicinal chemistry letters. 2025 04 22; 16(5).
865-874
ACS medicinal chemistry letters. 2025 04 22; 16(5).
865-874
Abstract
This Letter describes the discovery of novel mGlu NAMs and . Starting from previously reported picolinamide compounds, a structure-activity relationship study of various core isosteres was conducted, leading to the identification of thieno[3,2-]pyridine-5-carboxamide and 2,3-difluorobenzamide as competent core replacements. These compounds are highly potent as well as brain penetrant with an IVIVC agreement and improved oral bioavailability in rats.